Nimenrix Dosage/Direction for Use

Posology: Nimenrix should be used in accordance with available official recommendations. (See Table 18):

Click on icon to see table/diagram/image

Long-term antibody persistence data following vaccination with Nimenrix are available up to 10 years after vaccination (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Nimenrix may be given as a booster dose to individuals who have previously received primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines (see Pharmacology: Pharmacodynamics under Actions).
Special populations: Individuals who have underlying conditions predisposing them to meningococcal infection due to anatomic or functional asplenia (such as sickle cell disease) may receive at least one dose of Nimenrix (see Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).
Method of administration: Nimenrix is for intramuscular injection only.
In infants, the recommended injection site is the anterolateral aspect of the thigh. In individuals from 1 year of age, the recommended injection site is the anterolateral aspect of the thigh or deltoid muscle (see Precautions and Interactions).
For instructions on reconstitution of the medicinal product before administration, see Special Precautions for Disposal and Other Handling under Cautions for Usage.